CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
Clinical trial NCT04933422 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT04933422
- Sponsor
- Crimson Biopharm Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2027-01-01
- Primary completion
- 2029-07-01
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.